Skip to main content
Top
Published in: Health Economics Review 1/2017

Open Access 01-12-2017 | Research

Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS

Authors: Kjell Hausken, Mthuli Ncube

Published in: Health Economics Review | Issue 1/2017

Login to get access

Abstract

A four-period game is developed between a policy maker, the international community, and the population. This research supplements, through implementing strategic interaction, earlier research analyzing "one player at a time". The first two players distribute funds between preventing and treating diseases. The population reacts by degree of risky behavior which may cause no disease, disease contraction, recovery, sickness/death. More funds to prevention implies less disease contraction but higher death rate given disease contraction. The cost effectiveness of treatment relative to prevention, country specific conditions, and how the international community converts funds compared with the policy maker in a country, are illustrated. We determine which factors impact funding, e.g. large probabilities of disease contraction, and death given contraction, and if the recovery utility and utility of remaining sick or dying are far below the no disease utility. We also delineate how the policy maker and international community may free ride on each other’s contributions. The model is tested against empirical data for 43 African countries. The results show consistency between the theoretical model and empirical estimates. The paper argues for the need to create commitment mechanisms to ensure that free riding by both countries and the international community is avoided.
Footnotes
1
Examples are diseases which are infectious, airborne (pathogens may be viruses, bacteria, or fungi), non-communicable (e.g. heart disease, cancer), foodborne (consuming food with pathogenic bacteria, toxins, viruses, prions, parasites, etc.), or involve lifestyle (e.g. sedentary lifestyle, diets with refined carbohydrates, trans fats, alcohol, drugs, etc.).
 
2
We use the word international community to cover private and public financial donors, which also can come from within the given country from actors not associated with the country’s policy maker.
 
3
Recovery from a chronic disease such as HIV is impossible, but both prevention and treatment may ensure that the disease does not progress into AIDS causing death.
 
5
Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Chad, Congo, Democratic Rep., Cote d'Ivoire, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, São Tomé and Príncipe, Senegal, Sierra Leone, South Africa, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe.
 
Literature
2.
go back to reference Atun R, Chang AY, Ogbuoji O, Silva S, Resch S, Hontelez J, Bärnighausen T. Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study. BMJ Open. 2016;6(3): .doi:10.1136/bmjopen-2015-009656. Atun R, Chang AY, Ogbuoji O, Silva S, Resch S, Hontelez J, Bärnighausen T. Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study. BMJ Open. 2016;6(3): .doi:10.​1136/​bmjopen-2015-009656.
3.
go back to reference Bertozzi S, Padian NS, Wegbreit J, DeMaria LM, Feldman B, Gayle H, Isbell MT. HIV/AIDS prevention and treatment. Disease control priorities in developing countries. 2006;2:331–70. Bertozzi S, Padian NS, Wegbreit J, DeMaria LM, Feldman B, Gayle H, Isbell MT. HIV/AIDS prevention and treatment. Disease control priorities in developing countries. 2006;2:331–70.
8.
go back to reference Cohen D, Shin-Yi W, Farley T. Cost-Effective Allocation Of Government Funds To Prevent HIV Infection. Health Affairs. 2005;24(4):915–26.CrossRefPubMed Cohen D, Shin-Yi W, Farley T. Cost-Effective Allocation Of Government Funds To Prevent HIV Infection. Health Affairs. 2005;24(4):915–26.CrossRefPubMed
9.
go back to reference Collier P, Sterck O, Manning R. The Moral and Fiscal Implications of Anti-Retroviral Therapies for HIV in Africa (Vol. 2015-05): Centre for the Study of African Economies, University of Oxford. 2015. Collier P, Sterck O, Manning R. The Moral and Fiscal Implications of Anti-Retroviral Therapies for HIV in Africa (Vol. 2015-05): Centre for the Study of African Economies, University of Oxford. 2015.
11.
go back to reference Daniels N, Sabin J. Accountability for Reasonable Priority Setting. In: Akabayashi A, editor. The future of bioethics: international dialogues. Oxford: Oxford University Press; 2014. Daniels N, Sabin J. Accountability for Reasonable Priority Setting. In: Akabayashi A, editor. The future of bioethics: international dialogues. Oxford: Oxford University Press; 2014.
13.
go back to reference Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Freedberg KA. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings — The Case of Côte d'Ivoire. The New England Journal of Medicine. 2006;355(11):1141–53. doi:10.1056/NEJMsa060247.CrossRefPubMed Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Freedberg KA. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings — The Case of Côte d'Ivoire. The New England Journal of Medicine. 2006;355(11):1141–53. doi:10.​1056/​NEJMsa060247.CrossRefPubMed
16.
17.
go back to reference HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making. PLoS Medicine. 2012;9(7):e1001259. doi:10.1371/journal.pmed.1001259.CrossRef HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making. PLoS Medicine. 2012;9(7):e1001259. doi:10.​1371/​journal.​pmed.​1001259.CrossRef
19.
go back to reference Izazola-Licea JA, Wiegelmann J, Arán C, Guthrie T, De Lay P, Avila-Figueroa C. Financing the response to HIV in low-income and middle-income countries. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009;52:S119–26.CrossRefPubMed Izazola-Licea JA, Wiegelmann J, Arán C, Guthrie T, De Lay P, Avila-Figueroa C. Financing the response to HIV in low-income and middle-income countries. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009;52:S119–26.CrossRefPubMed
20.
go back to reference Kremer M, Glennerster R. Strong medicine : creating incentives for pharmaceutical research on neglected diseases. Princeton: Princeton University Press; 2004. Kremer M, Glennerster R. Strong medicine : creating incentives for pharmaceutical research on neglected diseases. Princeton: Princeton University Press; 2004.
21.
go back to reference Kremer M, Snyder CM. Why are drugs more profitable than vaccines? vol. 9833. Cambridge: National Bureau of Economic Research; 2003.CrossRef Kremer M, Snyder CM. Why are drugs more profitable than vaccines? vol. 9833. Cambridge: National Bureau of Economic Research; 2003.CrossRef
22.
go back to reference Kremer M, Snyder CM. Preventatives versus Treatments. USA: Department of Economics, Harvard University; 2015. Kremer M, Snyder CM. Preventatives versus Treatments. USA: Department of Economics, Harvard University; 2015.
23.
go back to reference Kumaranayake L, Watts C, Dixon S, Mc Donald S, Roberts J. Resource allocation and priority setting of HIV/AIDS interventions: addressing the generalized epidemic in sub‐Saharan Africa. Journal of International Development. 2001;13(4):451–66. doi:10.1002/jid.797.CrossRef Kumaranayake L, Watts C, Dixon S, Mc Donald S, Roberts J. Resource allocation and priority setting of HIV/AIDS interventions: addressing the generalized epidemic in sub‐Saharan Africa. Journal of International Development. 2001;13(4):451–66. doi:10.​1002/​jid.​797.CrossRef
24.
go back to reference Mamani H, Chick SE, Simchi-Levi D. A game-theoretic model of international influenza vaccination coordination. Management Science. 2013;59(7):1650–70.CrossRef Mamani H, Chick SE, Simchi-Levi D. A game-theoretic model of international influenza vaccination coordination. Management Science. 2013;59(7):1650–70.CrossRef
26.
go back to reference Moxnes JF, Hausken K. Mathematical modelling of acute virus influenza A infections. Mathematical and Computer Modelling of Dynamical Systems. 2012;18(5):521–38.CrossRef Moxnes JF, Hausken K. Mathematical modelling of acute virus influenza A infections. Mathematical and Computer Modelling of Dynamical Systems. 2012;18(5):521–38.CrossRef
27.
go back to reference Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention Handbook of economic evaluation of HIV prevention programs. New York: Springer; 1998. p. 135–52. Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention Handbook of economic evaluation of HIV prevention programs. New York: Springer; 1998. p. 135–52.
28.
go back to reference Thomas P. Big shot : passion, politics, and the struggle for an AIDS vaccine. New York: Public Affairs; 2001. Thomas P. Big shot : passion, politics, and the struggle for an AIDS vaccine. New York: Public Affairs; 2001.
29.
go back to reference Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy and Planning. 2003;18:4–17.CrossRefPubMed Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy and Planning. 2003;18:4–17.CrossRefPubMed
Metadata
Title
Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS
Authors
Kjell Hausken
Mthuli Ncube
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Health Economics Review / Issue 1/2017
Electronic ISSN: 2191-1991
DOI
https://doi.org/10.1186/s13561-016-0139-x

Other articles of this Issue 1/2017

Health Economics Review 1/2017 Go to the issue